Researchers said they saw no new safety signals for TCZ in the study.
“This research argues for systematic screening for aortitis at diagnosis,” Dr. Samson said. “And furthermore, we think that (in) further studies we need to better identify the patients that really need tocilizumab for GCA and optimal duration of this therapy in the course of disease.”
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Thomas R. Collins is a freelance writer living in South Florida.
References
- De Boysson H, Arquizan C, Boulouis G, et al. Maintenance therapy improves long-term outcomes in patients with primary angiitis of the central nervous system [abstract 975]. Arthritis Rheumatol. 2016;68 (suppl 10).
- Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomized, double-blind, placebo-controlled Phase 3 trial in Japan [abstract 976]. Arthritis Rheumatol. 2016;68 (suppl 10).
- Samson M, Devilliers H, Ly KH, et al. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment for giant cell arteritis: Results of a French multicenter prospective open-label study [abstract 977]. Arthritis Rheumatol. 2016;68(suppl 10).
- Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014 Dec;73(12):2074–2081.
